Wells Fargo
ATRA icon

Wells Fargo’s Atara Biotherapeutics ATRA Stock Holding History

Wells Fargo’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-32
Closed -$3K – 6380
2018
Q2 		$3K Sell
32
-8
-20% -$8.59K ﹤0.01% 6133
2018
Q1 		$4K Buy
+40
New +$36.5K ﹤0.01% 6089

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wells Fargo's ATRA Position: Q2 2026 in Review

Wells Fargo held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 251 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #6319.

Wells Fargo first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $14.2M in Q2 2018. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Wells Fargo held 251 shares of Atara Biotherapeutics worth $2.88K as of Q2 2026.
  • Wells Fargo left its Atara Biotherapeutics share count unchanged in Q2 2026.
  • Atara Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6319 holding.
  • Wells Fargo first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
  • Wells Fargo's Atara Biotherapeutics position peaked at $14.2M in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.